2024ASH | 多发性骨髓瘤微小残留病灶研究进展

2024 ASH

第66届美国血液学年会（ASH）将于2024年12月7日~10日在美国圣地亚哥召开。ASH作为全球血液学工作者的盛会，每年都会公布和发表世界各国的最新血液学进展。届时将汇集各国知名血液病学专家，分享全球最前沿的研究进展和突破性临床数据。本文为大家带来 多发性骨髓瘤微小残留病灶研究进展速递 ，让我们一起看看都有哪些研究吧！

摘要号： 365

标题： Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial

GEM2017FIT试验中，新诊断老年患者的外周残留病灶（PRD）和微小残留病灶（MRD）的临床价值

链接：

https://ash.confex.com/ash/2024/webprogram/Paper209748.html

摘要号： 491

标题： Total Diffusion Volume Evaluated By Whole-Body Diffusion Weighted Magnetic Resonance Image for the Assessment of Tumor Burden in Multiple Myeloma; Relations with Measurable Residual Disease Evaluated By Next-Generation Flow Cytometry and Bone Marrow CD138 Staining Assessed By Qupath

通过全身扩散加权磁共振成像评估的总扩散体积用于多发性骨髓瘤肿瘤负荷的评估；与通过二代流式细胞术评估的可测量残留病灶和通过Qupath评估的骨髓CD138染色之间的相关性

链接：

https://ash.confex.com/ash/2024/webprogram/Paper199873.html

摘要号： 4716

标题： Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

评估基线风险分层、移植后可测量残留病灶与多发性骨髓瘤长期结局之间的相互作用

链接：

https://ash.confex.com/ash/2024/webprogram/Paper211755.html

摘要号： 1962

标题： Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients

利用移植前骨髓微小残留病灶评估中二代流式细胞术检测的自体移植物中克隆性浆细胞的预测价值：针对多发性骨髓瘤患者的研究

链接：

https://ash.confex.com/ash/2024/webprogram/Paper204692.html

摘要号： 1968

标题： Soluble B-Cell Maturation Antigen As a Serum Marker of Minimal Residual Disease in Patients with Multiple Myeloma

可溶性B细胞成熟抗原作为多发性骨髓瘤患者血清中微小残留病灶的标志物

链接：

https://ash.confex.com/ash/2024/webprogram/Paper210899.html

摘要号： 3325

标题： NGS-Based Immunoglobulin Gene Sequencing for Diagnosis and MRD Monitoring of Multiple Myeloma

基于NGS（二代测序技术）的免疫球蛋白基因测序用于多发性骨髓瘤的诊断和微小残留病灶（MRD）监测

链接：

https://ash.confex.com/ash/2024/webprogram/Paper209254.html

摘要号： 3338

标题： Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma